The multi-center, randomized, double-blind, parallel-arm, placebo-controlled Phase 2/3 clinical study of opaganib for severe COVID-19 patients is planned to be […]
Investigational New Drug (IND) application submitted; Company preparing to initiate Phase 3 trialReDUX4 interim analysis in facioscapulohumeral dystrophy (FSHD) on […]